Welcome to our dedicated page for Assertio Holdings news (Ticker: ASRT), a resource for investors and traders seeking the latest updates and insights on Assertio Holdings stock.
Company Overview
Assertio Holdings Inc (ASRT) is a specialized pharmaceutical company committed to advancing patient care through a focused portfolio of FDA-approved products. The company operates primarily in the areas of neurology, orphan treatments, and specialty medicines, targeting conditions that demand innovative approaches to symptom management and quality of life improvements. With robust commercial capabilities, Assertio leverages both traditional sales forces and modern non-personal promotion strategies to effectively reach healthcare providers and payor networks.
Core Business and Product Portfolio
At its core, Assertio not only markets but also strategically acquires and licenses approved products that solve unmet medical needs. Among its prominent offerings are products approved for neurological indications, including therapies designed to manage postherpetic neuralgia, acute migraine treatments, and formulations aimed at moderating mild to moderate pain. These products are carefully developed and maintained in compliance with rigorous FDA standards, which underscores the company’s commitment to safety and efficacy.
Innovative Commercial Strategy
The company has built a diversified and resilient business model by integrating multiple marketing channels. Through a dedicated sales force and a streamlined non-personal promotion model, Assertio ensures that its treatments are accessible to clinicians and patients across various market segments. This dual approach not only enhances market penetration but also supports effective payor contracting and trade distribution, helping the company maintain a competitive edge in a sector marked by stringent regulatory and competitive pressures.
Market Position and Differentiation
Assertio’s competitive positioning is anchored in its strategic acquisition of established products and its innovative push into emerging therapeutic areas such as oncology. With assets like Rolvedon, the company has demonstrated adaptability and growth in targeted clinical segments. This asset, among others, reflects a forward-thinking and entrepreneurial spirit, aiming to expand patient access and improve treatment outcomes while navigating a complex pharmaceutical landscape. The company’s unwavering commitment to quality and patient-centric care is evident in its rigorous clinical standards and attention to regulatory compliance.
Operational Excellence and Commercial Capabilities
- Extensive Marketing Infrastructure: A combination of traditional and digital promotion channels tailored to maximize product outreach.
- Robust Distribution Network: Strategic partnerships and agreements with key payors facilitate wide and efficient market access.
- Acquisition and Licensing Strategy: A focused portfolio built through thoughtful acquisitions and licensing of clinically validated products.
Expertise and Industry Insight
Assertio exemplifies deep industry expertise by aligning its operational strategies with current trends in pharmaceutical development and market dynamics. The company uses a data-driven approach to decision-making, ensuring that its commercial strategies, regulatory compliance, and product development efforts are both effective and forward compatible. This level of meticulous operational management builds confidence among stakeholders and positions Assertio as a key player in the specialty pharmaceutical space.
Conclusion
In summary, Assertio Holdings Inc stands out as a commercial pharmaceutical company that harmonizes innovation with proven business models. Its commitment to developing and distributing differentiated, FDA-approved treatments illustrates a balanced approach to addressing both current patient needs and market challenges. The company’s integrated commercial infrastructure and focus on quality make it an informative subject for investors seeking deep insights into a specialized segment of the pharmaceutical industry.
Assertio Holdings, Inc. (ASRT) reported a 7% increase in fourth quarter net product sales to $32.2 million and $109.4 million for the full year 2021, driven by price favorability for Cambia and Indocin. The non-GAAP adjusted EBITDA surged 118% year-over-year to $17.8 million in Q4. The company provided 2022 guidance for net product sales between $126 million and $136 million and adjusted EBITDA from $64 million to $72 million. Assertio completed the acquisition of Otrexup, contributing to its growth strategy.
Assertio Holdings (NASDAQ: ASRT) will release its fourth quarter and full year 2021 financial results on March 9, 2022, before markets open. A live webcast of the earnings conference call is scheduled for 9:00 AM ET the same day. Investors can access details via the investor relations website. Assertio focuses on creating a differentiated pharmaceutical portfolio through product innovation and acquisitions.
Assertio Holdings (NASDAQ: ASRT) announced participation in the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. CEO Dan Peisert and CFO Paul Schwichtenberg will represent the company. An investor presentation is now available for on-demand viewing on the Assertio Investor Relations website for 30 days. Assertio focuses on commercializing differentiated pharmaceutical products in neurology, hospital care, and pain management. For more details, visit Assertio's website.
Assertio Holdings, Inc. (Nasdaq: ASRT) has announced the acquisition of Otrexup (methotrexate) from Antares Pharma for a total of $44 million, including $18 million paid upfront. This acquisition, the first since 2015, aims to enhance Assertio's growth and leverage its digital platform for commercialization. Assertio raised its full-year net product sales guidance to over $108 million and adjusted EBITDA to over $48 million for 2021, fueled by strong existing product sales and expected contributions from Otrexup.
Assertio Holdings, Inc. (ASRT) announced a preliminary settlement agreement regarding three shareholder derivative lawsuits against its subsidiary, Assertio Therapeutics, approved by the California Superior Court. The lawsuits, alleging breaches of fiduciary duties among other claims, will lead to corporate governance changes lasting at least two years. Assertio will also pay $150,000 in legal fees, subject to court approval. A settlement hearing is scheduled for December 14, 2021, to finalize the agreement and address any objections from current stockholders.
Assertio, a pharmaceutical company, reported Q3 2021 financial results, achieving net product sales of $25.997 million and a net income of $3.737 million. This marks a significant improvement from a net loss of $10.522 million in Q3 2020. The company raised its full-year net product sales guidance to over $103 million and adjusted EBITDA guidance to exceed $43 million. Sequentially, Assertio generated $4.7 million in operating cash flows, its highest since Q4 2019, while settling legal uncertainties, including a $7 million antitrust litigation settlement.
Assertio Holdings, Inc. (NASDAQ: ASRT) will announce its third quarter 2021 financial results on November 4, 2021, after market close. A conference call is scheduled for 4:30 p.m. Eastern Time on the same day. Stakeholders can join the call using the provided dial-in numbers: 1 (844) 200-6205 for domestic and 1 (929) 526-1599 for international participants. Assertio is known for its differentiated pharmaceutical products in the fields of neurology, hospital, and pain and inflammation.
Assertio Holdings, Inc. (NASDAQ: ASRT) announced investor presentations at several upcoming conferences. CEO Dan Peisert and CFO Paul Schwichtenberg will present at the LD Micro Main Event from October 12-14, 2021, the Stifel 2021 Virtual Healthcare Conference from November 15-17, and the Q4 Investor Summit from November 16-17. Additionally, they will participate in the Sidoti & Company Virtual Microcap Conference on December 8-9. Detailed information and live webcasts will be available on their investor website.
Assertio Holdings, Inc. reported net product sales of $24.8 million for Q2 2021, a significant increase from $20.2 million in Q2 2020. The company also raised its full year guidance for net product sales to $91-$96 million, up from $85-$92 million. Despite a net loss of $14.2 million in Q2, improved execution of cost-saving measures is expected to enhance adjusted EBITDA to between $34-$37 million. The company's transition to a non-personal promotional model has also contributed positively.
In addition, a legal reserve of $11.3 million was established, and the company regained compliance with NASDAQ after a reverse stock split.
Assertio Holdings (NASDAQ: ASRT) plans to release its second quarter 2021 financial results on August 5, 2021, after market close. A conference call hosted by management will follow at 4:30 p.m. Eastern Time. Investors can access the live webcast and replay on the company's investor website. Assertio specializes in pharmaceutical products in neurology, hospital, and pain management. The company has achieved growth through licensing, mergers, and acquisitions.
FAQ
What is the current stock price of Assertio Holdings (ASRT)?
What is the market cap of Assertio Holdings (ASRT)?
What is the core business of Assertio Holdings Inc?
How does Assertio generate its revenue?
What are some key products in Assertio's portfolio?
How does the company achieve market access for its products?
What makes Assertio’s business model unique?
How does Assertio position itself against competitors?
What are the key commercial capabilities of Assertio?
Is there evidence of Assertio’s industry expertise?
